Immunotherapy of cancer is living through a revolutionary period prompted by the extraordinary efficacy results of antibodies blocking CTLA-4 or PD-1/PD-L1 against a variety of solid cancers [1, 2] . In parallel, durable clinical responses are achieved by adoptive T cell therapy against B cell lineage leukemias and lymphomas, using genetransduced T lymphocytes to express chimeric antigen receptors recognizing the B cell marker CD19 [3] [4] [5] . Very likely, significant additional benefit of innovative immunotherapy will result from combinatorial approaches [1, 2] , as recently reported by combining anti-PD1-and anti-CTLA-4-targeted therapy in a phase III clinical trial for metastatic melanoma patients [6] that was conducive to FDA approval. As yet clinically unexplored avenue, combining adoptive T cell therapy with immune-augmenting strategies could additionally increase the efficacy of immune control in solid tumors and improve outcome.
Immunotherapy of cancer is living through a revolutionary period prompted by the extraordinary efficacy results of antibodies blocking CTLA-4 or PD-1/PD-L1 against a variety of solid cancers [1, 2] . In parallel, durable clinical responses are achieved by adoptive T cell therapy against B cell lineage leukemias and lymphomas, using genetransduced T lymphocytes to express chimeric antigen receptors recognizing the B cell marker CD19 [3] [4] [5] . Very likely, significant additional benefit of innovative immunotherapy will result from combinatorial approaches [1, 2] , as recently reported by combining anti-PD1-and anti-CTLA-4-targeted therapy in a phase III clinical trial for metastatic melanoma patients [6] that was conducive to FDA approval. As yet clinically unexplored avenue, combining adoptive T cell therapy with immune-augmenting strategies could additionally increase the efficacy of immune control in solid tumors and improve outcome. CD137 (4-1BB, tnfrsf9) is a surface receptor of the TNF receptor family that is expressed by activated but not resting T lymphocytes and NK cells [7] . Expression on T cells requires antigen recognition since it requires intense signaling through the antigen receptor complex. Therefore, only T cells that have been antigen-primed acquire the expression of CD137, the downstream signaling of which promotes T cell proliferation, memory differentiation, and effector functions and further prevents T cell apoptosis [8] . Under physiological circumstances, this receptor is ligated by CD137 ligand (4-1BB ligand), an agonist membrane molecule expressed by professional antigen-presenting cells, but also by some tumor cells. In order to exploit this pathway therapeutically, monoclonal antibodies which achieve much stronger, supraphysiological stimulation of CD137 signaling were designed to enhance costimulation of CD8 T lymphocytes and strongly improve the defense against syngeneic Abstract CD137(4-1BB) costimulation and adoptive T cell therapy strongly synergize in terms of achieving maximal efficacy against experimental cancers. These costimulatory biological functions of CD137 have been exploited by means of introducing the CD137 signaling domain in clinically successful chimeric antigen receptors and to more efficiently expand T cells in culture. In addition, immunomagnetic sorting of CD137-positive T cells among tumor-infiltrating lymphocytes selects for the fittest antitumor T lymphocytes for subsequent cultures. In mouse models, co-infusion of both agonist antibodies and T cells attains marked synergistic effects that result from more focused and intense cytolytic activity visualized under in vivo microscopy and from more efficient entrance of T cells into the tumor through the vasculature. These several levels of dynamic interaction between adoptive T cell therapy and CD137 offer much opportunity to raise the efficacy of current cancer immunotherapies.
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Abbreviations
CAR
Chimeric antigen receptor CART Chimeric antigen receptor T cell CTL Cytotoxic T lymphocyte TIL Tumor-infiltrating lymphocyte transplanted tumors [9] . Primarily, the mechanism of action is mediated by cytolytic T lymphocytes (CTLs) [9] which kill tumor cells in a perforin/granzyme-dependent fashion [10] . Recently, we have discovered a critical role for BATF-3-dependent dendritic cells in cross priming CTLs against tumor antigens for the efficacy of anti-CD137 agonist monoclonal antibodies [11] . Direct and indirect effects of agonist anti-4-BB mAbs on regulatory T cells and susceptibility of effector T cells to regulatory T cells have been reported [12] even though the importance of such proposed mechanisms in CD137-based immunotherapy [13] remains to be fully elucidated.
It has been shown in mouse models that anti-CD137 mAbs are synergistic with anti-PD-L1 and anti-OX40 immunostimulatory monoclonal antibodies against spontaneous tumors [14] , as well as with adoptive T cell therapy [15] . Antihuman CD137 mAbs urelumab [16, 17] and PF-05082566 are being developed with interesting efficacy results as monotherapy [18, 19] . As a potential caveat of application of urelumab, dose-dependent liver toxicity has resulted in a 10-fold dose reduction relative to the maximum efficacious dose in early trials. Liver inflammation had been observed in mouse models [20] as a side effect that has taken place in humans as a life-threatening dose-limiting toxicity in patients undergoing clinical trials at doses superior to 1 mg/kg of urelumab [16] . Of note, PF-05082566 dose escalation has been reported to be largely uneventful in terms of liver toxicity [19] . Therefore, to maximize efficacy and minimize side effects, combination therapy of urelumab is of prime interest, and realized in ongoing clinical trials combining anti-CD137 and anti-PD-1 mAbs (NCT02253992, NCT02179918).
To consolidate the concept of anti-CD137 mAb-based immune augmentation, combined use with adoptive T cell therapy is particularly attractive, based on four lines of synergistic mechanisms (Figs. 1 and 2 ):
1. CD137 expression allows for the selection of the best fitted T cells among cultures of tumor-infiltrating lymphocytes. Immunomagnetic sorting can be applied to retrieve and concentrate these lymphocytes for further culture, thereby selecting for lymphocytes with antitumor activity [21, 22] . 2. Culture in the presence of the antibody used for selection conditions and stimulates the T cells so the yield of the cultures is more abundant while showing better antitumor performance upon subsequent adoptive T cell transfer in mouse models of cancer [23, 24] . Addition of 4-1BB agonist antibodies when expanding TIL or CAR T cells increases both quantitative yield and qualitative cytolytic capacity on a per-cell basis. 3. Administration of anti-CD137 mAbs to mice which had been TIL adoptively transferred results in synergistic effects. This is mainly mediated by costimulation of the infused T lymphocytes [25] , but also by enhancing T cell entry into malignant tissue through a direct proinflammatory effect on tumor-associated endothelial cells that ectopically express CD137 [26] . 4 . It has been shown that in the CAR constructs based on single-chain antibodies linked to intracellular signaling domains of CD3ζ, those bearing the costimulatory intracellular domain of CD137 have the greatest antitumor immunity. Indeed, the most successful trials based on adoptive transfer of CAR transduced T cells incorporate the intracellular domain of CD137 [4, 27] .
We have recently reported [28] synergistic immune effects using intravital time-lapse two-photon microscopy of adoptively transferred tumor-specific CD8 T cells infiltrating B16F10 melanomas in the absence or presence of anti-CD137 agonist antibodies (Fig. 2) . Using tumor cells marked with a fluorescent histone and using genetically fluorescent T cells, we are able to obtain dynamic estimates of the migration and tumor-killing as well as mitosis and apoptosis rates of the transferred T cells and melanoma cells (Fig. 3) . In this synergistic experimental setting, the behavior of cytotoxic T cells is modified under the influence of anti-CD137 mAbs, so T cells exert more focused activity against the tumor cells, with (1) improved tumor infiltration capability based on enhanced migration and (2) prolonged engagement with tumor cells followed by apoptosis induction. Clues from these experiments are important to guide clinical trials of combination approaches. Caution is needed since the mechanisms accounting for side effects of adoptive T cell therapy and its preconditioning regimens can interact with those of anti-CD137 mAbs leading 
